FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118700500> ?p ?o ?g. }

• W2118700500 endingPage "1410" @default.
• W2118700500 startingPage "1410" @default.
• W2118700500 abstract "<h3>Objectives</h3>To quantify response rates of S ézary syndrome (SS) to multimodality immunomodulatory therapy and to identify the important prognostic parameters that affect overall response to treatment.<h3>Design</h3>Retrospective cohort study.<h3>Setting</h3>Cutaneous T-cell lymphoma clinic at The Hospital at the University of Pennsylvania.<h3>Participants</h3>Ninety-eight patients who met the revised International Society for Cutaneous Lymphomas (ISCL) and the European Organization of Research and Treatment of Cancer (EORTC) criteria for the diagnosis of SS and were seen over a 25-year period at the University of Pennsylvania.<h3>Intervention</h3>Patients were treated with at least 3 months of extracorporeal photopheresis and 1 or more systemic immunostimulatory agents.<h3>Main Outcome Measures</h3>Overall response to treatment was the main measurement of outcome.<h3>Results</h3>A total of 73 patients had significant improvement with multimodality therapy: 30% had complete response, with clearing of all disease (n = 29), and 45% had partial response (n = 44). At baseline, the complete response group had a lower CD4/CD8 ratio than the nonresponse group (13.2 vs 44.2) (P = .04) and a lower median percentage of CD4⁺/CD26⁻ cells (27.4% vs 57.2%) (P = .01) and CD4⁺/CD7⁻ cells (20.0% vs 41.3%) (P < .01). Median monocyte percentage at baseline was higher for patients who had a complete response than for nonresponders (9.5% vs 7.3%) (P = .02). The partial response group did not have any statistically significant variables compared with the nonresponse group.<h3>Conclusions</h3>In this large cohort study of patients with SS, a high clinical response rate was achieved using multiple immunomodulatory therapies. A lower CD4/CD8 ratio, a higher percentage of monocytes, and lower numbers of circulating abnormal T cells at baseline were the strongest predictive factors for complete response compared with nonresponse and warrant further examination in a larger cohort." @default.
• W2118700500 created "2016-06-24" @default.
• W2118700500 creator A5003572409 @default.
• W2118700500 creator A5003991725 @default.
• W2118700500 creator A5015108124 @default.
• W2118700500 creator A5015306391 @default.
• W2118700500 creator A5021690954 @default.
• W2118700500 creator A5023391744 @default.
• W2118700500 creator A5027555412 @default.
• W2118700500 creator A5039751986 @default.
• W2118700500 creator A5061211377 @default.
• W2118700500 creator A5067235495 @default.
• W2118700500 creator A5069916535 @default.
• W2118700500 creator A5085181595 @default.
• W2118700500 date "2011-12-01" @default.
• W2118700500 modified "2023-10-17" @default.
• W2118700500 title "High Clinical Response Rate of S ézary Syndrome to Immunomodulatory Therapies" @default.
• W2118700500 cites W149648231 @default.
• W2118700500 cites W1930495262 @default.
• W2118700500 cites W1973176723 @default.
• W2118700500 cites W2013497426 @default.
• W2118700500 cites W2013894560 @default.
• W2118700500 cites W2014281715 @default.
• W2118700500 cites W2014608550 @default.
• W2118700500 cites W2029239441 @default.
• W2118700500 cites W2040940474 @default.
• W2118700500 cites W2044158364 @default.
• W2118700500 cites W2048282576 @default.
• W2118700500 cites W2080831532 @default.
• W2118700500 cites W2096843411 @default.
• W2118700500 cites W2113624410 @default.
• W2118700500 cites W2114449557 @default.
• W2118700500 cites W2145155871 @default.
• W2118700500 cites W2147180662 @default.
• W2118700500 cites W2155652724 @default.
• W2118700500 cites W2162093324 @default.
• W2118700500 cites W233460929 @default.
• W2118700500 cites W2346164771 @default.
• W2118700500 cites W2100103468 @default.
• W2118700500 doi "https://doi.org/10.1001/archdermatol.2011.232" @default.
• W2118700500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21844430" @default.
• W2118700500 hasPublicationYear "2011" @default.
• W2118700500 type Work @default.
• W2118700500 sameAs 2118700500 @default.
• W2118700500 citedByCount "36" @default.
• W2118700500 countsByYear W21187005002012 @default.
• W2118700500 countsByYear W21187005002013 @default.
• W2118700500 countsByYear W21187005002014 @default.
• W2118700500 countsByYear W21187005002015 @default.
• W2118700500 countsByYear W21187005002016 @default.
• W2118700500 countsByYear W21187005002017 @default.
• W2118700500 countsByYear W21187005002018 @default.
• W2118700500 countsByYear W21187005002019 @default.
• W2118700500 countsByYear W21187005002020 @default.
• W2118700500 countsByYear W21187005002022 @default.
• W2118700500 countsByYear W21187005002023 @default.
• W2118700500 crossrefType "journal-article" @default.
• W2118700500 hasAuthorship W2118700500A5003572409 @default.
• W2118700500 hasAuthorship W2118700500A5003991725 @default.
• W2118700500 hasAuthorship W2118700500A5015108124 @default.
• W2118700500 hasAuthorship W2118700500A5015306391 @default.
• W2118700500 hasAuthorship W2118700500A5021690954 @default.
• W2118700500 hasAuthorship W2118700500A5023391744 @default.
• W2118700500 hasAuthorship W2118700500A5027555412 @default.
• W2118700500 hasAuthorship W2118700500A5039751986 @default.
• W2118700500 hasAuthorship W2118700500A5061211377 @default.
• W2118700500 hasAuthorship W2118700500A5067235495 @default.
• W2118700500 hasAuthorship W2118700500A5069916535 @default.
• W2118700500 hasAuthorship W2118700500A5085181595 @default.
• W2118700500 hasBestOaLocation W21187005001 @default.
• W2118700500 hasConcept C126322002 @default.
• W2118700500 hasConcept C143998085 @default.
• W2118700500 hasConcept C167135981 @default.
• W2118700500 hasConcept C167672396 @default.
• W2118700500 hasConcept C203014093 @default.
• W2118700500 hasConcept C2776694085 @default.
• W2118700500 hasConcept C2776780870 @default.
• W2118700500 hasConcept C2777756187 @default.
• W2118700500 hasConcept C2779338263 @default.
• W2118700500 hasConcept C2781468836 @default.
• W2118700500 hasConcept C3019096185 @default.
• W2118700500 hasConcept C71924100 @default.
• W2118700500 hasConcept C8891405 @default.
• W2118700500 hasConcept C90924648 @default.
• W2118700500 hasConceptScore W2118700500C126322002 @default.
• W2118700500 hasConceptScore W2118700500C143998085 @default.
• W2118700500 hasConceptScore W2118700500C167135981 @default.
• W2118700500 hasConceptScore W2118700500C167672396 @default.
• W2118700500 hasConceptScore W2118700500C203014093 @default.
• W2118700500 hasConceptScore W2118700500C2776694085 @default.
• W2118700500 hasConceptScore W2118700500C2776780870 @default.
• W2118700500 hasConceptScore W2118700500C2777756187 @default.
• W2118700500 hasConceptScore W2118700500C2779338263 @default.
• W2118700500 hasConceptScore W2118700500C2781468836 @default.
• W2118700500 hasConceptScore W2118700500C3019096185 @default.
• W2118700500 hasConceptScore W2118700500C71924100 @default.
• W2118700500 hasConceptScore W2118700500C8891405 @default.
• W2118700500 hasConceptScore W2118700500C90924648 @default.

• next